Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay

YC Barrett, Z Wang, C Frost… - Thrombosis and …, 2010 - thieme-connect.com
Apixaban and other factor Xa (FXa) inhibitors are in late-stage clinical development for
prevention and treatment of thromboembolic diseases. Although routine monitoring will not …
被引用次数：479 相关文章

Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay

YC Barrett, Z Wang, C Frost… - Thrombosis and …, 2010 - thieme-connect.com
Apixaban and other factor Xa (FXa) inhibitors are in late-stage clinical development for
prevention and treatment of thromboembolic diseases. Although routine monitoring will not …

[引用][C] Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay

YC BARRETT, Z WANG, C FROST… - Thrombosis and …, 2010 - pascal-francis.inist.fr
Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to
prothrombin time assay CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic …

Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.

YC Barrett, Z Wang, C Frost… - Thrombosis and …, 2010 - europepmc.org
Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to
prothrombin time assay. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …

Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay

Z Wang, C Frost, A Shenker, YC Barrett - Thrombosis and Haemostasis, 2010 - cir.nii.ac.jp
抄録< jats: title> Summary</jats: title>< jats: p> Apixaban and other factor Xa (FXa) inhibitors
are in late-stage clinical development for prevention and treatment of thromboembolic …

Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay

YC Barrett, Z Wang, C Frost… - Thrombosis and …, 2010 - pubmed.ncbi.nlm.nih.gov
Apixaban and other factor Xa (FXa) inhibitors are in late-stage clinical development for
prevention and treatment of thromboembolic diseases. Although routine monitoring will not …

[引用][C] Clinical laboratory measurement of direct factor Xa inhibitors: anti‐Xa assay is preferable to prothrombin time assay

YC Barrett - Thromb Haemost, 2010 - cir.nii.ac.jp
Clinical laboratory measurement of direct factor Xa inhibitors: anti‐Xa assay is preferable to
prothrombin time assay | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …

[引用][C] Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay

YC BARRETT, W ZHAOQING, C FROST… - Thrombosis and …, 2010 - Schattauer